Roche takes Tecentriq hit on survival data

Roche's hopes of clinching more of the lung cancer treatment market with its Tecentriq immunotherapy had a major setback on Thursday, when a trial failed to deliver survival data the Swiss drugmaker needs to challenge rival Merck.

from Reuters: Health https://ift.tt/2zUCFes
via IFTTT

• Tweet
• Share
• Share
• Share
• Share